Skip to Main Content

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Conditions

Diseases of the Kidney & Urinary Tract

Phase III

What is the purpose of this trial?

Brief Summary:

Primary Objective:

Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).

Secondary Objectives:

  • Evaluate the safety profile of Hectorol® capsules versus Rocaltrol® (calcitriol) capsules.
  • Determine the pharmacokinetic profile of 1,25-dihydroxyvitamin D2 after administration of Hectorol®.
  • Trial with
    Sanofi
  • Start Date
    04/25/2019
  • End Date
    12/26/2019
Trial Image

For more information about this study, contact:

Novagrami George

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Sub-Investigator

  • Last Updated
    04/29/2019
  • Study HIC
    #2000022264